CTOs on the Move

Aco Med Supply

www.acomedsupply.com

 
Aco Med Supply is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Impact Advisors

Impact Advisors is a nationally recognized healthcare consulting firm that is solving some of the toughest challenges in the industry by delivering strategic advisory, implementation and optimization services. Our comprehensive suite of patient access, clinical and revenue cycle services span the lifecycle of our clients` needs. Our experienced team has a powerful combination of clinical, revenue, operations, consulting, and IT experience. The firm has earned a number of prestigious industry and workplace awards including Best in KLAS® for thirteen consecutive years, Healthcare Informatics HCI 100, Crain`s Chicago Business Fast Fifty, as well as multi-year “best place to work” awards from: Modern Healthcare, Consulting Magazine, Becker`s Hospital Review and Achievers.

ODS Companies

ODS Companies is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Citizens Choice Healthplan

Citizens Choice Healthplan is a Cerritos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Med League

Med League is a Flemington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fibrocell Science

Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.